Envoy Medical (COCH) to Release Quarterly Earnings on Thursday

Envoy Medical (NASDAQ:COCH) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $0.10 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH) last posted its earnings results on Monday, May 11th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts expect Envoy Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Envoy Medical Stock Performance

Shares of COCH opened at $0.67 on Tuesday. The company has a 50 day moving average price of $0.69 and a 200-day moving average price of $0.68. Envoy Medical has a fifty-two week low of $0.36 and a fifty-two week high of $1.89. The stock has a market capitalization of $51.82 million, a PE ratio of -0.67 and a beta of 1.88.

Institutional Investors Weigh In On Envoy Medical

Large investors have recently modified their holdings of the business. Focus Partners Wealth acquired a new position in shares of Envoy Medical during the first quarter valued at about $276,000. Geode Capital Management LLC increased its stake in Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after purchasing an additional 51,813 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Envoy Medical during the 3rd quarter valued at approximately $60,000. Hedge funds and other institutional investors own 8.59% of the company’s stock.

Analyst Ratings Changes

COCH has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a report on Tuesday, July 21st. Zacks Research raised Envoy Medical to a “hold” rating in a research report on Wednesday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of Envoy Medical in a report on Wednesday, July 15th. Finally, Loop Capital set a $2.00 price target on Envoy Medical in a research report on Monday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Envoy Medical has a consensus rating of “Hold” and an average price target of $2.25.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.